Literature DB >> 16982223

A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery.

Marianne S Elston1, Inge J Stewart, Roderick Clifton-Bligh, John V Conaglen.   

Abstract

Oncogenic osteomalacia is a rare condition characterized by a low serum phosphate, reduced tubular reabsorption of phosphate and a low or inappropriately normal 1,25 dihydroxyvitamin D and is usually secondary to a phosphaturic mesenchymal tumor. Complete tumor resection results in resolution of all features. We report a patient with oncogenic osteomalacia and concurrent secondary hyperparathyroidism. Serum phosphate failed to normalize preoperatively with octreotide therapy, although this treatment did suppress serum FGF23. The postoperative course was distinguished by marked hyperphosphatemia that was associated with elevated serum 1,25 dihydroxyvitamin D concentrations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982223     DOI: 10.1016/j.bone.2006.07.027

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Phosphaturic Mesenchymal Tumor: 2 New Oral Cases and Review of 53 Cases in the Head and Neck.

Authors:  Hiba Qari; Aya Hamao-Sakamoto; Clay Fuselier; Yi-Shing Lisa Cheng; Harvey Kessler; John Wright
Journal:  Head Neck Pathol       Date:  2015-11-14

3.  Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.

Authors:  William H Hoffman; Alka Jain; Harold Chen; Neal S Fedarko
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

4.  [Metabolic bone diseases].

Authors:  F Jakob
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

5.  FGF23 Producing Mesenchymal Tumor.

Authors:  Lucyna Papierska; Jarosław B Cwikła; Waldemar Misiorowski; Michał Rabijewski; Krzysztof Sikora; Hubert Wanyura
Journal:  Case Rep Endocrinol       Date:  2014-02-03

Review 6.  A rare combination of tumor-induced osteomalacia caused by sinonasal glomangiopericytoma and coexisting parathyroid adenoma: case report and literature review.

Authors:  Agnieszka Brociek-Piłczyńska; Dorota Brodowska-Kania; Kornel Szczygielski; Małgorzata Lorent; Grzegorz Zieliński; Piotr Kowalewski; Dariusz Jurkiewicz
Journal:  BMC Endocr Disord       Date:  2022-01-28       Impact factor: 2.763

Review 7.  Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review.

Authors:  Huanwen Wu; Marilyn M Bui; Lian Zhou; Dongmei Li; Hui Zhang; Dingrong Zhong
Journal:  Mod Pathol       Date:  2018-09-11       Impact factor: 7.842

8.  Tumor induced osteomalacia in head and neck region: single center experience and systematic review.

Authors:  Ravikumar Shah; Anurag R Lila; Ramteke-Swati Jadhav; Virendra Patil; Abhishek Mahajan; Sushil Sonawane; Puja Thadani; Anil Dcruz; Prathamesh Pai; Munita Bal; Subhada Kane; Nalini Shah; Tushar Bandgar
Journal:  Endocr Connect       Date:  2019-10       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.